Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Grant Bischof

Physician Assistant Pinehurst, NC Physician Assistant

NPI 1306467709 CMS profile 11218403

10 Page Dr, Pinehurst, NC 28374

Open in the dashboard

General payments

$25,147

777 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Grant Bischof of Pinehurst, NC is reported in the CMS Open Payments database as having received $25,147 across 777 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,438 226
2024 General $3,800 205
2023 General $3,362 195
2022 General $1,934 112
2021 General $613 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Grant Bischof
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Grant Bischof were reported at $15,438. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Grant Bischof Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $613 $132 $37–$438 $132
2022 $1,934 $155 $48–$522 $149
2023 $3,362 $167 $52–$557 $160
2024 $3,800 $178 $55–$600 $164
2025 $15,438 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $12,378 133 payments
  2. TG Therapeutics, Inc. $1,136 44 payments
  3. Teva Pharmaceuticals USA, Inc. $762 33 payments
  4. Pfizer Inc. $719 48 payments
  5. Novartis Pharmaceuticals Corporation $715 48 payments
  6. UCB, Inc. $628 23 payments
  7. Jazz Pharmaceuticals Inc. $604 22 payments
  8. Lilly USA, LLC $603 25 payments
  9. Celgene Corporation $554 55 payments
  10. Argenx US, Inc. $505 19 payments
  11. Other $6,544 327 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,040 765 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,831 8 payments
  3. Travel and Lodging $189 3 payments
  4. Education $87 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $8,371 83 payments
  2. UBRELVY $4,166 81 payments
  3. BRIUMVI $1,136 44 payments
  4. NURTEC ODT $617 44 payments
  5. Epidiolex $588 22 payments
  6. ZEPOSIA $580 56 payments
  7. ZAVZPRET $528 37 payments
  8. KESIMPTA $494 35 payments
  9. Austedo XR $363 14 payments
  10. BOTOX $332 22 payments
  11. Other $9,794 485 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

7,951

Median for Physician Assistant: 241

Drug cost

$2,144,142

Median for Physician Assistant: $4,110

Branded share of claims

23%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 49 $517,514
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 17 $472,622
Austedo Deutetrabenazine Brand 14 $191,991
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 29 $154,721
Nurtec Odt Rimegepant Sulfate Brand 78 $125,488
Nuplazid Pimavanserin Tartrate Brand 21 $108,365
Ubrelvy Ubrogepant Brand 44 $82,956
Austedo Xr Deutetrabenazine Brand 11 $61,941
Nuedexta Dextromethorphan Hbr/Quinidine Brand 38 $58,542
Aimovig Autoinjector Erenumab-Aooe Brand 49 $42,916

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 52 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIUMVI
  • TG Therapeutics, Inc. $259
$259 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $244
$244 49 —
ZEPOSIA
  • Celgene Corporation $170
  • E.R. Squibb & Sons, L.L.C. $26
$196 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $132
  • Lundbeck LLC $49
$181 — —
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 52 with Patron

Records

777 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record